INDUCTIVE PRODUCTION OF PLURIPOTENT STEM CELLS USING SYNTHETIC TRANSCRIPTION FACTORS

The present invention relates to use of synthetic factors in reprogramming somatic cells to become induced pluripotent stem cells and other cell lineages. Specifically, the present application relates to fusion proteins containing proteins encoded by cell totipotency-related genes and transcription regulatory domains, their coding sequences, expression vectors, and compositions. The present application also relates to methods for reprogramming somatic cells to become induced pluripotent stem cells and other cell lineages, and cells containing the fusion proteins or the coding sequences. 1. A fusion protein , characterized in that the fusion protein comprisesa protein encoded by a gene related to cell totipotency or a fragment thereof, anda transcription regulatory domain or a fragment thereof having transcription regulatory activity.2. The fusion protein according to claim 1 , characterized in that the gene related to cell totipotency is selected from OCT4 claim 1 , NANOG claim 1 , SOX2 claim 1 , Tcl1 claim 1 , Tcf3 claim 1 , Rex1 claim 1 , Sal4 claim 1 , lefty1 claim 1 , Dppa2 claim 1 , Dppa4 claim 1 , Dppa5 claim 1 , Nr5a1 claim 1 , Nr5a2 claim 1 , Dax1 claim 1 , Esrrb claim 1 , Utf1 claim 1 , Tbx3 claim 1 , Grb2 claim 1 , Tel1 claim 1 , Sox15 claim 1 , Gdf3 claim 1 , Ecat1 claim 1 , Ecat8 claim 1 , Fbxo15 claim 1 , eRas claim 1 , or Foxd3.3. The fusion protein according to claim 1 , characterized in that the gene related to cell totipotency is selected from Oct4 claim 1 , NANOG claim 1 , or SOX2.4. The fusion protein according to characterized in that the protein encoded by the gene related to cell totipotency is selected from the amino acid sequence at positions127-352 of Oct4 or the amino acid sequence at positions 1-286 of Oct4.5. The fusion protein according to claim 1 , characterized in that the transcription regulatory domain is selected from a transcription regulatory domain of viral protein VP16 claim 1 , EBNA2 claim 1 , and E1A or a fragment thereof ...

DOT1 Histone Methyltransferases as a Target for Identifying Therapeutic Agents for Leukemia

The present invention provides polypeptides with histone H3 lysine 79 methyltransferase activity as well as nucleic acids encoding the same. Also provided are methods of using the polypeptides and nucleic acids of the invention in screening assays to identify compounds of interest. Further provided are diagnostic methods for leukemia and prognostic methods to predict the course of the disease in a subject. 146-. (canceled)47. A method of diagnosing whether a subject has or is at risk for developing leukemia and/or determining the prognosis for the course of the disease , comprising:obtaining a biological sample comprising nucleosomes from a subject;adding to the biological sample an antibody that binds to a methylated histone H3 lysine 79 (H3-K79);detecting the level of H3-K79 methylation associated with the HoxA9 gene;wherein an elevation in HoxA9-associated H3-K79 methylation in the biological sample as compared with the level of HoxA9-associated H3-K79 methylation in a non-leukemic biological sample is diagnostic that the subject has or is at risk of developing leukemia and/or is prognostic of the course of the disease in the subject.48. The method of claim 47 , wherein the biological sample is a cell or tissue sample.49. The method of claim 48 , wherein the biological sample is a B cell sample or bone marrow sample.50. The method of claim 47 , wherein the biological sample is a nucleosome preparation.51. The method of claim 47 , wherein the method further comprises detecting the level of histone H3 lysine 4 methylation associated with the HoxA9 gene. This invention was made with federal support under Grant Nos. GM63076 and GM68804 awarded by the National Institutes of Health/National Cancer Institute. The United States government has certain rights in the invention.This application claims the benefit of priority from U.S. provisional patent application Ser. No. 60/478,497, filed 13 Jun. 2003, which is incorporated herein by reference in its entirety.The present ...

Dot1 histone methyltransferases as a target for identifying therapeutic agents for leukemia

The present invention provides polypeptides with histone H3 lysine 79 methyltransferase activity as well as nucleic acids encoding the same. Also provided are methods of using the polypeptides and nucleic acids of the invention in screening assays to identify compounds of interest. Further provided are diagnostic methods for leukemia and prognostic methods to predict the course of the disease in a subject.

Compounds inhibiting tdg activity

The present invention provides a class of compounds inhibiting TDG activity. Specifically, the present invention provides a compound having a novel structure as shown in formula I. The small molecule inhibitor of the present invention has an excellent inhibitory effect on TDG.

Membrane electrode assembly with high-efficiency water and heat management for direct ethanol fuel cell, and fabrication method therefor

The present disclosure provides a membrane electrode assembly (MEA) with high-efficiency water and heat management for a direct ethanol fuel cell (DEFC), and a fabrication method therefor, and belongs to the technical field of fuel cells. In the MEA for a DEFC in the present disclosure, a cathode catalyst layer is designed to be convex and ordered and an anode catalyst layer is designed to be concave and ordered, which is conducive to the timely discharge of the generated heat. The MEA for a DEFC can be fabricated by gradually fabricating each layer of the MEA on an inner surface and an outer surface of a proton-exchange membrane (PEM) or by step-by-step dip coating on an anode support tube. The present disclosure can effectively improve the working capacity of the cell.

Dot1-histon-methyltransferasen als ziel zur identifizierung von therapeutika gegen leukämie

DEFC membrane electrode with efficient hydrothermal management capability, and preparation method therefor

Membrane electrode assembly with high-efficiency water and heat management for direct ethanol fuel cell, and fabrication method therefor

The present disclosure provides a membrane electrode assembly (MEA) with high-efficiency water and heat management for a direct ethanol fuel cell (DEFC), and a fabrication method therefor, and belongs to the technical field of fuel cells. In the MEA for a DEFC in the present disclosure, a cathode catalyst layer is designed to be convex and ordered and an anode catalyst layer is designed to be concave and ordered, which is conducive to the timely discharge of the generated heat. The MEA for a DEFC can be fabricated by gradually fabricating each layer of the MEA on an inner surface and an outer surface of a proton-exchange membrane (PEM) or by step-by-step dip coating on an anode support tube. The present disclosure can effectively improve the working capacity of the cell.

Compounds inhibiting tdg activity

The present invention provides a class of compounds inhibiting TDG activity. Specifically, the present invention provides a compound having a novel structure as shown in formula I. The small molecule inhibitor of the present invention has an excellent inhibitory effect on TDG.

Compounds inhibiting tdg activity

DEFC membrane electrode with efficient hydrothermal management capability, and preparation method therefor

A DEFC membrane electrode with an efficient hydrothermal management capability, and a preparation method therefor. A cathode catalytic layer (7) is designed to be of an outward protruding ordered type, and an anode catalytic layer (4) is designed to be of an inward recessed ordered type; and during the preparation of the DEFC membrane electrode, the membrane electrode can be prepared on a proton exchange membrane (8) towards an inner side and an outer side step by step, or the membrane electrode can be prepared by means of a coating method of performing impregnation on an anode support body tube (9) step by step. By means of the DEFC membrane electrode, the timely discharge of generated heat is facilitated, thereby improving the mass transfer efficiency; and the operating capability of a battery can be effectively improved.

Defc-membran-elektrode mit hocheffizienter wasser- und wärmemanagementfähigkeit und zugehöriges herstellungsverfahren

Die vorliegende Erfindung stellt eine DEFC-Membran-Elektrode mit hocheffizienter Wasser- und Wärmemanagementfähigkeit und ein zugehöriges Herstellungsverfahren bereit und gehört zu dem technischen Gebiet der Brennstoffzellen. Bei der erfindungsgemäßen DEFC-Membran-Elektrode ist eine Kathoden-Katalysatorschicht konvex und ordentlich gestaltet und eine Anoden-Katalysatorschicht konkav und ordentlich gestaltet, womit die rechtzeitige Abfuhr der erzeugten Wärme erleichtert wird; Bei der Herstellung der DEFC-Membran-Elektrode können zwei Verfahren verwendet werden, wobei also an einer Protonenaustauschmembran innen und außen beidseitig die Membran-Elektrode schrittweise hergestellt und an einem Anoden-Stützkörperrohr mittels eines Auftragungsverfahrens durch schrittweises Imprägnieren die Membran-Elektrode hergestellt wird Mit der vorliegenden Erfindung kann die Arbeitsfähigkeit der Zelle effektiv verbessert werden.

一种用于美丽乡村一体化公厕的组合式化粪池

本实用新型公开了一种用于美丽乡村一体化公厕的组合式化粪池，包括至少两个化粪池本体，化粪池本体一侧设有进粪口，化粪池本体另一侧设有出粪口，还包括混凝土底板和连接板，混凝土底板浇筑在地面上，连接板的底部通过螺钉固定连接有垫木，垫木预埋在地面中，连接板固定连接有至少四块夹紧板，单块混凝土底板浇筑于相邻两块夹紧板之间的区域中，化粪池本体砌筑在混凝土底板上。本实用新型能将多个化粪池本体设置在同一高度，使得化粪池本体的进粪口处于同一高度，便于逐一将化粪池本体的进粪口和公厕的粪尿排泄管进行连接，防止化粪池本体的进粪口和公厕的粪尿排泄管出现渗漏现象。

Modification of 5-methylcytosine catalyzed by Cmd1 enzyme and application thereof

The present invention relates to a novel modification of a 5-methylcytosine nucleic acid catalyzed by a Cmd1 enzyme and an application thereof. The present inventors have for the first time discovered Cmd1, a 5mC-modifying enzyme, which can link a glyceryl group to a 5mC methyl carbon of a methylated nucleic acid through a carbon-carbon single bond, and this is a new epigenetic modification.

DOT1 histone methyltransferases as a target for identifying therapeutic agents for leukemia

The present invention provides polypeptides with histone H3 lysine 79 methyltransferase activity as well as nucleic acids encoding the same. Also provided are methods of using the polypeptides and nucleic acids of the invention in screening assays to identify compounds of interest. Further provided are diagnostic methods for leukemia and prognostic methods to predict the course of the disease in a subject.